Thanks, Buzzmarr, my earlier comments; i.e., Bandit94536, were focused on interventional cardiology market. However, the feedback you've provided is a valuable perspective-builder.
While I agree with you that BSX is the market leader in interventional radiology, the acquisition of SciMed, Heart Technology and CVIS have contributed to its future financial success being more dependent on cardiology products than radiology. That's not to suggest that radiology won't remain critical to the success of the company but they are already the "big fish in a relatively small pond". The magnitude of the cardiology market is both in the relative size of the market segment relative to radiology and non-vascular as well as the much higher prices and profit margins.
Thus, the analysts are acutely focused on BSX's progress as it relates to coronary stents.